Chiara Lomazzi

Chiara Lomazzi

Auto-generated profile, based on publicly available information

Chiara Lomazzi

Vascular Surgery—Department of Cardio-Thoracic and Vascular Surgery, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico , Milan, 20122

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2021 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
VGViviana Grassi
Viviana Grassi
STSanti Trimarchi
Santi Trimarchi
FWFred Weaver
Fred Weaver
HBHector W L de Beaufort
Hector W L de Beaufort
AAAli Azzizzadeh
Ali Azzizzadeh
TPThe Great Participants
The Great Participants
: OBJECTIVES: The aim of this study was to evaluate the short- to mid-term outcomes of descending thoracic aortic aneurysm (DTAA) repair from the Gore Global Registry for Endovascular Aortic Treatment (GREAT). METHODS: This is a multicentre sponsored prospective observational cohort registry. The study population comprised those treated for DTAA receiving GORE thoracic aortic devices for DTAA repair between August 2010 and October 2016. Major primary outcomes were early and late survival, freedom from aorta-related mortality and freedom from aorta-related reintervention. RESULTS: There were 180 (58.1%) males and 130 (41.9%) females: the mean age was 70 ± 11 years (range 18–92). The median maximum DTAA diameter was 60 mm (interquartile range 54–68.8). Technical success was achieved in all patients. Operative mortality, as well as immediate conversion to open repair, was never observed. At the 30-day window, mortality occurred in 4 (1.3%) patients, neurological events occurred in 4 (1.3%) patients (transient ischaemic attacks/stroke n = 3, paraplegia n = 1) and the reintervention rate was 4.5% (n = 14). Estimated survival was 95.6% [95% confidence interval (CI) 92.6–97.4] at 6 months, 92.7% (95% CI 89.1–95.2) at 1 year and 57.3% (95% CI 48.5–65.1) at 5 years. Freedom from aorta-related mortality was 98.3% (95% CI 96.1–99.3) at 6 months, 98.3% (95% CI 96.1–99.3) at 1 year and 92.2% (95% CI 83.4–96.4) at 5 years. Freedom from thoracic endovascular aortic repair (TEVAR)-related reintervention at 5 years was 87.2% (95% CI 81.2–91.4). CONCLUSIONS: TEVAR for DTAAs using GORE thoracic aortic devices is associated with a low rate of device-related reinterventions and is effective at preventing aorta-related mortality for up to 5 years of follow-up. Clinical registration number: NCT number: NCT01658787. Subject collection: 161, 164.

1 July 2019 in Annals of Cardiothoracic Surgery
Verified
Journal Article
Open access
CLChiara Lomazzi
Chiara Lomazzi
VGViviana Grassi
Viviana Grassi
MDMaurizio Domanin
Maurizio Domanin
CVCarlo De Vincentiis
Carlo De Vincentiis
Gabriele PiffarettiGabriele Piffaretti
Gabriele Piffaretti
STSanti Trimarchi
Santi Trimarchi
Penetrating aortic ulcer (PAU) of the arch has a focal extent which often represents an adequate anatomic target for thoracic endovascular aortic repair (TEVAR). However, the anatomic constraints represented by the supra-aortic vessels pose either clinical or technical challenges that increase when the PAU develops proximally in the arch. Currently, different types of endografts are commercially available and have been used to treat aortic arch lesions. These include branched/fenestrated endografts for a total endovascular approach, and standard devices that can be used in combination with open/hybrid surgical operations, with the aim to exploit the minimally invasive nature of TEVAR by extending the proximal landing zone when necessary. We describe several current techniques adopted in such settings.

4 January 2022 in Phlebology: The Journal of Venous Disease
Verified
Journal Article
Closed access
PDF file
DBDaniele Bissacco
Daniele Bissacco
CMChiara Malloggi
Chiara Malloggi
CLChiara Lomazzi
Chiara Lomazzi
MDMaurizio Domanin
Maurizio Domanin
AOAndrea Odero
Andrea Odero
RCRenato Casana
Renato Casana
Quality of life (QoL) in patients with chronic venous disorders has a central role to decide the correct treatment approach. In particular, in case of mini-invasive therapy, such as endovenous radiofrequency ablation (RFA), the postoperative QoL improvement remains one of the most important outcome to be reached. Despite this, very few data are published on the long-term QoL modifications after RFA. The aim of this brief report is to describe and analyze the role of QoL scales in a population of patients treated with RFA of the great saphenous vein and phlebectomies, highlighting results in short- and long-term follow-up period, and differences between recanalized and non-recanalized patients.

1 May 2014
Verified
Journal Article
Open access
PDF file
STSanti Trimarchi
Santi Trimarchi
SSSara Segreti
Sara Segreti
VGViviana Grassi
Viviana Grassi
CLChiara Lomazzi
Chiara Lomazzi
CVCarlo De Vincentiis
Carlo De Vincentiis
VRVincenzo Rampoldi
Vincenzo Rampoldi
Emergent treatment of aortic rupture in acute type B dissection

3 July 2025 in Interdisciplinary CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
SASara Allievi
Sara Allievi
TMTim J Mandigers
Tim J Mandigers
FWFred A Weaver
Fred A Weaver
AAAli Azizzadeh
Ali Azizzadeh
Gabriele PiffarettiGabriele Piffaretti
Gabriele Piffaretti
STSanti Trimarchi
Santi Trimarchi
OBJECTIVES: This study evaluated the short- to longer-term safety and efficacy of extended thoracic endovascular aortic repair for Type B aortic dissection. METHODS: We identified acute and subacute Type B dissection between 2010 and 2016 in the Global Registry for Endovascular Aortic Treatment. We stratified the population based on treatment extent: ‘non-extended’ (1 stent graft deployed), ‘extended’ (>1 stent graft deployed). Our primary outcomes were in-hospital spinal cord ischaemia and mortality. Secondarily, we evaluated procedure-related complications (endoleak, migration, fracture, compression, reinterventions), sac dynamics, rupture, and all-cause mortality at 1 and 5 years. Sensitivity analysis was performed in patients without prior aortic procedures. RESULTS: Of 170 procedures, 78 (46%) were extended (median 2 [range 2–5] stent-grafts). Extended and non-extended treatment had similar rates of complicated presentations (53% vs 64%; P = 0.13). Compared with non-extended treatment, extended treatment had similar in-hospital rates of spinal cord ischaemia (2.6% vs 2.2%; P = 1) and mortality (2.6% vs 2.2%, P = 1). Additionally, extended treatment had not statistically different sac expansion rates, (1 year: 14% vs 23%, P =0.80; 5 years: 16% vs 32%, P=0.29) and rupture risk (1 year: 1.3% vs 3.3%, P = 0.63), similar procedure-related complications (endoleak, migration, fracture, compression, reinterventions; all P > 0.05) and all-cause mortality (1 year: 10% vs 7.6%, P=0.54; 5 years: 19% vs 21%, P=0.82). All outcomes remained similar on sensitivity analysis. CONCLUSIONS: Our findings suggest that extended treatment for Type B aortic dissection may be associated with similar procedure-related risks and complications. Future larger studies are needed to define who might benefit from an extended treatment and further optimize patient-specific treatment for aortic dissection.

20 January 2025 in European Heart Journal
Verified
Journal Article
Closed access
CLChiara Lomazzi
Chiara Lomazzi
JKJasper F de Kort
Jasper F de Kort
STSanti Trimarchi
Santi Trimarchi